MARKET

PLSE

PLSE

Pulse
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.13
+0.35
+3.25%
Closed 16:42 08/07 EDT
OPEN
10.77
PREV CLOSE
10.78
HIGH
11.44
LOW
10.71
VOLUME
55.98K
TURNOVER
--
52 WEEK HIGH
17.45
52 WEEK LOW
5.11
MARKET CAP
279.91M
P/E (TTM)
-4.7442
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PLSE stock price target is 16.00 with a high estimate of 16.00 and a low estimate of 16.00.

EPS

PLSE News

More
Pulse Biosciences, Inc. Appoints Richard van den Broek to Board of Directors
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company progressing Nano-Pulse StimulationTM (NPS™) technology, announced today the appointment of Richard van den Broek to its board of directors. In c
Business Wire · 3d ago
Pulse Biosciences Schedules Second Quarter 2020 Financial Results Conference Call for August 10, 2020
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS™) technology, announced today it will report financial results for the second quarter 2020 after market close on Monday, August 10, 2020. Compa
Business Wire · 07/27 20:05
Nano-Pulse Stimulation Technology Produces Favorable Results in Several Clinical Studies Presented at the 2020 Laser Medicine and Surgery Virtual Annual Conference
Business Wire · 07/01 21:05
Pulse Biosciences, Inc. Announces Closing of $30 Million Rights Offering
Business Wire · 06/17 01:12
Pulse Biosciences Reports Received Basic Subscriptions, Over Subscriptions For ~7.963M Units At Price Of $7.01/Unit; Maximum Number Of Up To ~4.28M Units Offered
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, announced today further details of its rights offering, which expired on June 8,
Benzinga · 06/10 13:18
Pulse Biosciences, Inc. Announces Preliminary Results for Its Oversubscribed Rights Offering
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company, today announced preliminary results of its rights offering, which expired at 5:00 p.m. Eastern Time on June 8, 2020 (the "Expiration Date").
Business Wire · 06/08 22:46
Pulse Biosciences, Inc. Announces Commencement of Rights Offering
Business Wire · 05/14 22:38
Pulse Biosciences, Inc Common Stock (PLSE) Q1 2020 Earnings Call Transcript
MotleyFool.com · 05/14 07:01

Industry

Advanced Medical Equipment & Technology
+0.47%
Healthcare Equipment & Supplies
+0.49%

Hot Stocks

Symbol
Price
%Change

About PLSE

Pulse Biosciences, Inc. is a clinical-stage medical device company using a platform technology called Nano-Pulse stimulating (NPS). NPS is a non-thermal, precise, focal drug-free electroceutical treatment technology that initiates cell death within treated tissue. NPS provides treatment in a range of immuno-oncology, dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret's esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing PulseTx system (PulseTx), a system for the delivery of NPS treatments. The PulseTx system delivers NPS pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.
More

Webull offers kinds of Pulse Biosciences Inc stock information, including NASDAQ:PLSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLSE stock methods without spending real money on the virtual paper trading platform.